Vsee Health regains Nasdaq compliance after equity increase
DUBLIN - Investment firm TIG Advisors, LLC has disclosed a 1.59% stake in Avadel Pharmaceuticals plc, according to a regulatory filing submitted Thursday.
The disclosure, made under the Irish Takeover Panel rules, reveals that TIG Advisors holds 1,548,112 ordinary shares in the pharmaceutical company as of October 23, 2025.
The filing details multiple purchase transactions executed on the same day, with TIG Advisors acquiring a total of 975,000 shares at prices ranging from $18.50 to $18.52 per share.
The largest single transaction involved the purchase of 400,000 shares at $18.50 per share, followed by 150,000 shares at $18.52. Several additional purchases of 100,000, 75,000, and 50,000 shares were also reported.
The disclosure was made under Rule 8.3 of the Irish Takeover Panel Act, which requires public disclosure when an entity acquires interests in relevant securities representing 1% or more of a company that may be involved in a potential takeover situation.
The filing indicates that TIG Advisors holds no short positions in Avadel Pharmaceuticals and has no cash-settled or stock-settled derivative positions in the company.
Avadel Pharmaceuticals, headquartered in Dublin, Ireland, is listed on the Nasdaq exchange. The company specializes in developing pharmaceutical products focused on central nervous system conditions.
The information was disclosed through a Form 8.3 filing submitted to the Regulatory Information Service.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.